Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, China; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Department of Hepatobiliary and Pancreas Surgery, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong Province, China.
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):564-570. doi: 10.1016/j.bbcan.2017.10.002. Epub 2017 Oct 17.
It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a significant survival benefit from the sorafenib treatment, which is currently regarded as a first-line chemotherapeutic therapy in patients with advanced HCC. Most patients are highly refractory to this therapy. Therefore, it is necessary to identify resistant factors and explore potential protocols that can be used to overcome the resistance or substitute sorafenib once the resistance is formed. In fact, a growing body of studies has been focusing on the resistance mechanisms or the method to overcome it. The limitation of sorafenib efficacy has been partially but not fully elucidated. Moreover, some protocols have shown encouraging outcomes but still need to be further verified in clinical trials. In this review, we summarize the recent findings on the potential mechanisms that contribute to sorafenib resistance and discuss strategies that can be used to improve the treatment outcome.
令人失望的是，只有少数肝细胞癌（HCC）患者从索拉非尼治疗中获得显著的生存获益，目前该药物被认为是晚期 HCC 患者的一线化疗药物。大多数患者对此治疗高度耐受。因此，有必要确定耐药因素，并探索潜在的方案，以克服耐药性或在形成耐药性时替代索拉非尼。事实上，越来越多的研究集中在耐药机制或克服耐药性的方法上。索拉非尼疗效的局限性已部分阐明，但尚未完全阐明。此外，一些方案已显示出令人鼓舞的结果，但仍需要在临床试验中进一步验证。在这篇综述中，我们总结了导致索拉非尼耐药的潜在机制的最新发现，并讨论了可以用来改善治疗效果的策略。
